Last update 01 Nov 2024

HIV p17 matrix protein

Last update 01 Nov 2024

Basic Info

Synonyms-

Introduction-

Drugs associated with HIV p17 matrix protein

AT-20

Target

HIV p17 matrix protein

Mechanism

HIV p17 matrix protein inhibitors

Active Org.

Medestea Internazionale Srl

Originator Org.

Medestea Internazionale Srl

Active Indication

HIV Infections

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

AT-96

Target

HIV p17 matrix protein

Mechanism

HIV p17 matrix protein inhibitors

Active Org.-

Originator Org.

Medestea Research & Production SpA

Active Indication-

Inactive Indication

HIV Infections

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with HIV p17 matrix protein

100 Translational Medicine associated with HIV p17 matrix protein

0 Patents (Medical) associated with HIV p17 matrix protein

Literatures (Medical) associated with HIV p17 matrix protein

30 Apr 2024·Journal of General Virology

Molecular mechanisms behind the generation of pro-oncogenic HIV-1 matrix protein p17 variants

Article

Author: Zani, Alberto ; Caccuri, Francesca ; Caruso, Arnaldo ; Messali, Serena ; Uggeri, Matteo ; Sclavi, Leonardo ; Bugatti, Antonella ; Rondina, Alessandro

HIV-1 matrix protein p17 variants (vp17s), characterized by amino acid insertions at the COOH-terminal region of the viral protein, have been recently identified and studied for their biological activity. Different from their wild-type counterpart (refp17), vp17s display a potent B cell growth and clonogenic activity. Recent data have highlighted the higher prevalence of vp17s in people living with HIV-1 (PLWH) with lymphoma compared with those without lymphoma, suggesting that vp17s may play a key role in lymphomagenesis. Molecular mechanisms involved in vp17 development are still unknown. Here we assessed the efficiency of HIV-1 Reverse Transcriptase (RT) in processing this genomic region and highlighted the existence of hot spots of mutation in Gag, at the end of the matrix protein and close to the matrix-capsid junction. This is possibly due to the presence of inverted repeats and palindromic sequences together with a high content of Adenine in the 322–342 nucleotide portion, which constrain HIV-1 RT to pause on the template. To define the recombinogenic properties of hot spots of mutation in the matrix gene, we developed plasmid vectors expressing Gag and a minimally modified Gag variant, and measured homologous recombination following cell co-nucleofection by next-generation sequencing. Data obtained allowed us to show that a wide range of recombination events occur in concomitance with the identified hot spots of mutation and that imperfect events may account for vp17s generation.

01 Feb 2024·Journal of Virological Methods

Detection of HIV-1 matrix protein p17 in sera of viremic and aviremic patients

Article

Author: Zani, Alberto ; Uggeri, Matteo ; Caruso, Arnaldo ; Caccuri, Francesca ; Bonfanti, Carlo ; Messali, Serena

People living with human immunodeficiency virus type 1 (HIV-1), even if successfully treated with a combined antiretroviral therapy, display a persistent inflammation and chronic immune activation, and an increasing risk of developing cardiovascular and thrombotic events, cancers, and neurologic disorders. Accumulating evidence reveals that biologically active HIV-1 proteins may play a role in the development of these HIV-1-associated conditions. The HIV-1 matrix protein p17 (p17) is released and accumulates in different organs and tissue where it may exert multiple biological activities on different target cells. To assess a role of p17 in different HIV-1-related pathological processes, it is central to definitively ascertain and quantitate its expression in a large number of sera obtained from HIV-1-infected (HIV-1⁺) patients. To this aim, we developed a specific and highly sensitive p17 capture immunoenzymatic assay. Data obtained highlight a heterogeneous expression of p17 in blood of tested patients, with patients who were negative or displayed from low to relatively high p17 blood concentrations (range from 0.05 to 7.29 nM). Moreover, we found that blood p17 concentration was totally independent from the viremic status of the patient. This finding calls for monitoring HIV-1⁺ patients in order to evaluate a possible correlation between p17 amount in blood and the likelihood of developing HIV-1-related pathological conditions.

01 Sep 2022·Pathology - Research and Practice

High expression of HIV-1 matrix protein p17 in both lymphoma and lymph node tissues of AIDS patients

Article

Author: Feng, Yanling ; Song, Shu ; Yang, Yuexiang ; Guo, Wenjuan ; Li, Duoduo ; Zhang, Renfang ; Wang, Ao ; Lu, Hongzhou ; Zheng, Ye ; Shi, Yuhan ; Zeng, Dong ; Wang, Zhenyan ; Wu, Minmin ; Xu, Jingjing

BACKGROUNDHIV-1 matrix protein p17 was found to be associated with lymphoma development in vitro. This study aimed to elucidate the pathogenetic roles of HIV-1 p17 in AIDS-related lymphoma.METHODSExpression of HIV-1 proteins p17, p24, nef and tat were evaluated in tumor tissue samples from 60 lymphoma patients and lymph node samples from 23 non-lymphoma patients with HIV-1 infection by immunohistochemistry. Microvascular density (MVD) determined by CD34 were also assessed in tumor tissues. Clinicopathological data of AIDS patients with lymphoma were collected retrospectively.RESULTSThe subtypes of lymphoma among sixty AIDS patients were diffuse large B-cell lymphoma (32 cases), Burkitt lymphoma (23 cases), Hodgkin's lymphoma (4 cases), and plasmablastic lymphoma (1 case). The expression rate of HIV-1 p17 in lymphoma and non-lymphoma group was 63 % (38/60) and 61 % (14/29) respectively, with no significant difference (p = 0.835). The positive expression rate of p17 in both groups was significantly higher than that of p24, nef and tat (p < 0.05). The expression of p17 was associated with a higher MVD in the lymphoma group (p < 0.05). There were no significant differences in the 2-years overall survival between p17 positive and negative group (61 % vs. 50 %, p = 0.525).CONCLUSIONThe common expression of HIV-1 matrix protein p17 in both lymphoma and lymph node tissues of AIDS patients and the association between p17 expression and the higher MVD suggest that the accumulation and persistence of p17 in tissues may play a role in lymphoma development.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

HIV p17 matrix protein

Basic Info

Related

Analysis